摘要
目的观察舍曲林治疗躯体形式障碍的临床疗效和不良反应。方法采用开放式临床研究方法,收集60例躯体形式障碍患者,接受可变剂量的舍曲林治疗8周。在治疗前和治疗后第1、2、4、8周末分别采用症状自评量表(SCL-90)躯体化因子和临床总体印象量表(CGI-SI)评定,用不良反应症状量表(TESS)评定并记录药物的不良反应。结果57例完成8周试验。总有效率为80.7%,显效率49.1%。治疗后SCL-90躯体化因子评分和CGI-SI评分较治疗前明显降低,差异有统计学意义(P<0.01)。常见的不良反应为头晕、嗜睡和体质量增加等,程度较轻。结论舍曲林治疗躯体形式障碍的疗效肯定,不良反应少,安全性依从性好。
Objective To observe the clinical efficacy and side effects of sertraline in the treatment of somatoform disorders. Methods Sixty patients with somatoform disorders were assigned to receive sertraline for eight weeks, the patients were measured with clinical globalimpression scale（CGI-SI） and somatization in symptom checklist 90（SCL-90） before treatment and at1 th,2nd,4th, 8th weekend after treatment, the treatment emergent symptoms scale（TESS） was used to assess the side effects at 1th,2nd,4th,8th weekend after treatment. Results Fifty-seven patients with somatoform disorders finished the whole eight-week trail. The total effective rate and obvious effective rate were 80. 70/00 and 49. 1~ respectively. The score of SCL-90 somatoform gene and the CGI-SI score were all declined after treatment, there was significant difference before and after treatment （P 〈0.01）.The common side effects of sertraline were headache, decreasing food appetite, insomnia and so on. Conclusion Sertraline is an effective and safe drug to treat the patients with somatoform disorders.
出处
《中国实用神经疾病杂志》
2009年第8期14-16,共3页
Chinese Journal of Practical Nervous Diseases
关键词
舍曲林
躯体形式障碍
Sertraline
Somatoform disorders
